Search PubMed⌕ Search

Biomedical subjects

L A Price

Publications and source records attributed to L A Price.

At least 55 records · Page 3Linked to original sources
PubMed1982

Safe and effective induction chemotherapy without cisplatin for squamous cell carcinoma of the head and neck: impact on complete response rate and survival at five years, following local therapy.

One hundred forty-seven patients were given a kinetically based combination of vincristine, bleomycin, methotrexate, 5-fluorouracil, and hydrocortisone as initial treatment. Chemotherapy was given on days 1 and 14 before local "curative" therapy with radiation and/or surgery was started on day 28. Response to chemotherapy was assessed in 136 patients. In 89 stage III or IV patients, 57 (64%) responded and 32 (36%) did not. The complete remission (CR) rate following local therapy in patients responding to initial chemotherapy was 74% (42 patients). In patients not responding to initial chemotherapy the CR rate following local therapy was only 40%. This difference is highly significant (P less than 0.001). In 39 stage II patients, 28 (72%) responded to initial chemotherapy and 11 (28%) did not. After local therapy in this group the figures for CR were 70% (19 patients) and 73% (8 patients), respectively. This difference is not significant. Side effects from chemotherapy were minimal and patient compliance was 100%. Of the original 96 eligible patients studied, 1 patient was not assessed and 66 (69%) responded to initial chemotherapy; of these 48 (73%) had a CR following local therapy. Only 15 of the 29 chemotherapy nonresponders (52%) achieved CR following local therapy. This difference is significant (P = 0.03). The overall 5-year survival for these 96 patients is 36%, with chemotherapy responders having the longest median duration of survival.

Adult↗
PubMed1981

Safe and effective combination chemotherapy without cis-platinum for squamous cell carcinomas of the head and neck.

Different combinations of "standard" antitumor drugs were given to patients with squamous cell carcinomas of the head and neck. One hundred fifty-five patients received a combination of vincristine, bleomycin, methotrexate, hydrocortisone, and 5-fluorouracil given over 24 hours every 2 to 3 weeks. In patients who had received no previous treatment, 57 of 76 assessable patients (75%) responded. In previously treated patients, 20 of 40 assessable patients responded (50%). Prior radiation significantly reduced response to chemotherapy. A response to initial chemotherapy increases the likelihood of successful local treatment. In this study, response to drug treatment was not affected by age, sex, histology, or site. Crude survival at 2 years is significantly increased in responding patients compared with a historically matched control group when chemotherapy is given before radiation therapy or surgery. Preliminary results of a randomized prospective controlled study suggest that primary adjuvant chemotherapy without cis-platinum may significantly increase survival in this group of patients.

Antineoplastic Agents↗
PubMed1981

Cell population kinetics - experimental methods and their in vivo relevance for human cancer chemotherapy.

The value of certain concepts derived from experimental studies of stem cell kinetics are discussed in terms of their clinical relevance. The application of these principles involving treatment for approximately 24 hours on an intermittent basis as soon as bone marrow recovery has occurred, has been shown clinically markedly to increase the safety and selectivity of cancer chemotherapy. Examples are given for treating breast carcinomas, head and neck tumours and bronchogenic carcinomas. In vitro studies with established cell lines have confirmed the observation in tumour-bearing mice that exposure for a 24 hour period results in two types of dose response curves for the stem cell populations, which form the basis for the Kinetic Classification of Antitumour Agents. This simple in vitro system is now being used to classify newer antitumour agents. Attempts to extend these studies to consider stem cells in human tumours are described together with their problems and limitations.

Animals↗
PubMed1979

Cancer trials.

Explore the source record for details and available documents.

Clinical Trials as Topic↗
PubMed1979

Cancer chemotherapy.

Explore the source record for details and available documents.

Antineoplastic Agents↗
PubMed1978

Improved results in combination chemotherapy of head and neck cancer using a kinetically-based approach: a randomised study with and without adriamycin.

One hundred and seventeen patients with advanced squamous cell carcinoma of the head and neck were randomised between two combination schedules, one with and the other without adramycin. Responses (more than 50% tumor regression) were 67% overall with 63% responding to the combination without adriamycin and 82% responding to the schedule containing it. The increase in response rate seen with the addition of adriamycin is not statistically significant. Prior radiotherapy reduced the likelihood of response to chemotherapy.

Antineoplastic Agents↗